Oncogenex Pharma (OGXI) 0.55 $OGXI Biotech Stock

New Post Public Reply Private Reply Replies (0) Message Board

Sep 1, 2016 at 11:06 PM

Oncogenex Pharma (OGXI) 0.55 $OGXI

Biotech Stock Roundup: Vertex Slips on Study Halt, Aurinia Plunges on Lupus Data
Arpita Dutt - Zacks Investment Research - Wed Aug 17, 2:49PM CDT
With second quarter earnings season drawing to a close, focus in back on pipeline and regulatory updates.
BIIB: 306.03 (+0.40), VRTX: 94.75 (+0.24), AUPH: 1.95 (+0.01), OGXI: 0.55 (+0.01), GILD: 77.42 (-0.96), AVEO: 0.91 (-0.02), AMGN: 170.13 (+0.07)

OncoGenex Down on Poor Phase III Data on Lead Cancer Drug
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 8:57AM CDT
Shares of OncoGenex Pharmaceuticals, Inc. (OGXI) were down 41% after the company announced disappointing data from its late-stage trial, AFFINITY, on custirsen in men with metastatic castrate-resistant prostate cancer.
OGXI: 0.55 (+0.01), ANIP: 61.42 (+1.68), CORT: 5.35 (+0.02), PCRX: 40.37 (+0.74)

OncoGenex Announces Results from the Phase 3 AFFINITY Trial of Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer
CNW Group - Tue Aug 16, 6:00AM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today results from the final analysis of AFFINITY, the Phase 3 trial of custirsen in men with metastatic castrate-resistant prostate cancer (CRPC) whose disease has progressed after treatment with docetaxel. The trial did not meet the primary endpoint of demonstrating a statistically significant improvement in overall survival for patients treated with custirsen in combination with cabazitaxel/prednisone compared to cabazitaxel/prednisone alone.
OGXI: 0.55 (+0.01)

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2016
PR Newswire - Thu Aug 04, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its second quarter 2016 financial results and provided a summary of anticipated milestones.
OGXI: 0.55 (+0.01)

Rexahn's Drugs Deal a Death Blow to Solid Tumor Cancer
ACCESSWIRE - Thu May 19, 8:01AM CDT
Efficacy in Gemzar-resistant cancer is proven
RNN: 0.25 (unch), OGXI: 0.55 (+0.01), AMGN: 170.13 (+0.07), LLY: 77.23 (-0.52), BMY: 56.76 (-0.63), MNTA: 12.15 (+0.13), CELG: 106.37 (-0.37), EXEL: 11.35 (+0.20)

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2016
PR Newswire - Thu May 12, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its first quarter 2016 financial results and provided a summary of anticipated milestones.
OGXI: 0.55 (+0.01)

OncoGenex to Report First Quarter 2016 Financial Results on May 12, 2016
PR Newswire - Thu Apr 28, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it will report its first quarter 2016 financial results on Thursday, May 12, 2016. Company management will host a conference call and live webcast at 4:30 p.m. Eastern Time to provide an overview of financial results, clinical development programs and a general corporate update.
OGXI: 0.55 (+0.01)

Analyst Review and Estimates; OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI)
ACCESSWIRE - Tue Apr 26, 1:05PM CDT
BOTHELL, WA and VANCOUVER, BC / ACCESSWIRE / April 26, 2016 / OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company's segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company's product candidates include Custirsen, Apatorsen and OGX-225. The Company is focused on targeting these particular proteins to disable the tumor cell's adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies. Of these product candidates, Custirsen and Apatorsen are clinical-stage assets. Custirsen is being evaluated in two Phase III trials. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27 (Hsp27). OGX-225 is a product candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins-2 and -5 (IGFBP-2, IGFBP-5). There are a several analyst covering OGXI's securities. The focus of the following report is several analyst rating and the companies drug pipeline and progress.
OGXI: 0.55 (+0.01)

Trending Stocks: Four of Wall Street's Most Active Equities on April 26, 2016
ACCESSWIRE - Tue Apr 26, 11:12AM CDT
MIAMI, FL / ACCESSWIRE / April 26, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. OGXI, LPTN, UPL, and CPLP have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
OGXI: 0.55 (+0.01), UPL: 0.31 (unch), CPLP: 3.52 (-0.03), LPTN: 2.37 (+0.02)

These 4 Small Cap Stocks Are Having Big Volume Days Today
ACCESSWIRE - Tue Apr 26, 9:38AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / The Stock Expert is issuing a report on four stocks that are performing well this Tuesday. SEED, OGXI, NVIV and TCS are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
NVIV: 6.89 (-0.15), OGXI: 0.55 (+0.01), SEED: 2.20 (-0.02), TCS: 5.35 (+0.03)

OncoGenex Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
PR Newswire - Tue Apr 05, 3:02PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that John Bencich, Chief Financial Officer at OncoGenex, will present at the 15th Annual Needham Healthcare Conference on April 13, 2016 at the Westin Grand Central Hotel in New York City.
OGXI: 0.55 (+0.01)

OncoGenex Announces Reduction in Force to Extend Cash Runway and Align Operations with Clinical Development Priorities
CNW Group - Thu Feb 04, 3:01PM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it is implementing a plan to reduce operating expenses, including a workforce reduction of approximately 27%. The Company expects cost savings associated with the reduction of employees and consultants, together with the elimination of certain planned expenditures not required for the completion of ongoing trials, will extend cash runway into the third quarter of 2017.
OGXI: 0.55 (+0.01)

OncoGenex Cancer Drug Fails to Show PFS in Phase II Trial
Zacks Equity Research - Zacks Investment Research - Thu Jan 21, 11:50AM CST
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that apatorsen failed to achieve the primary endpoint in an ongoing mid-stage study for NSCLC.
IMDZ: 7.11 (+0.06), EARS: 1.71 (-0.14), OGXI: 0.55 (+0.01), CORT: 5.35 (+0.02)

OncoGenex Announces Update on Phase 2 Spruce Trial in Previously Untreated Metastatic Non-Small Cell Lung Cancer
PR Newswire - Wed Jan 20, 3:01PM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data from the Phase 2 Spruce(TM) trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit. A potential PFS benefit was observed in patients with high baseline serum Hsp27 status when treated with apatorsen. The study is ongoing and overall survival results are expected in the second half of 2016.
OGXI: 0.55 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Beef 'O' Brady's Expands Into Tuscaloosa Market

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

KINGRVER Boosts RV Comfort with New Water Heater Lineup

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Employment Law Suit Hits ABC: Alleged Wage Violations

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...